• Goldenwell Biotech flagged non-reliance on financial statements in its March 31, June 30, and Sept. 30, 2025 Form 10-Q filings.
• Auditor Michael Gillespie & Associates cited a US GAAP error tied to a $9,840 legal invoice dated Sept. 23, 2025.
• Legal costs for services from May 21, 2024 to Sept. 23, 2025 were recorded in the wrong quarter, prompting planned amendments.
• Restatement targeted by about June 30, 2026; amendments expected to recognize $2,280, $2,200, and $2,080 of legal fees across the quarters.
• Company also identified revenue recognition timing errors on a service contract, plus misclassification of OTC Markets Group prepaid fees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Goldenwell Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-003440), on May 27, 2026, and is solely responsible for the information contained therein.